{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:12:34Z","timestamp":1784970754203,"version":"3.55.0"},"reference-count":117,"publisher":"Elsevier","isbn-type":[{"value":"9780128200766","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.irn.2020.03.022","type":"book-chapter","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T17:05:16Z","timestamp":1595264716000},"page":"3-50","source":"Crossref","is-referenced-by-count":43,"title":["Status and future directions of clinical trials in Alzheimer's disease"],"prefix":"10.1016","member":"78","reference":[{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neuroscience.2004.06.031","article-title":"Hepatocyte growth factor as an enhancer of nmda currents and synaptic plasticity in the hippocampus","volume":"128","author":"Akimoto","year":"2004","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.022_bb0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","article-title":"2019 Alzheimer's disease facts and figures","volume":"15","author":"Alzheimer's Association","year":"2019","journal-title":"Alzheimer's & Dementia"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.022_bb0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","article-title":"Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): A randomised, placebo-controlled trial","volume":"16","author":"Andrieu","year":"2017","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.022_bb0025","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","article-title":"Intranasal insulin improves memory in humans","volume":"29","author":"Benedict","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/bs.irn.2020.03.022_bb9000","unstructured":"Biogen News Releases. (2020). Biogen completes submission of biologics licence application to FDA for aducanumab as a treatment for Alzheimer's disease. July-8th. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-completes-submission-biologics-license-application-fda."},{"issue":"6","key":"10.1016\/bs.irn.2020.03.022_bb0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: A randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2020.03.022_bb0035","series-title":"Comprehensive medicinal chemistry II","first-page":"193","article-title":"Neurodegeneration","author":"Bozyczko-Coyne","year":"2007"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.022_bb0040","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00401-014-1356-1","article-title":"Are cases with tau pathology occurring in the absence of A\u03b2 deposits part of the AD-related pathological process?","volume":"128","author":"Braak","year":"2014","journal-title":"Acta Neuropathologica"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0045","first-page":"255","article-title":"Clinical development of aducanumab, an anti-Abeta human monoclonal antibody being investigated for the treatment of early Alzheimer's disease","volume":"4","author":"Budd Haeberlein","year":"2017","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"10139","key":"10.1016\/bs.irn.2020.03.022_bb0050","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(18)31425-9","article-title":"Alzheimer's disease research: The future of BACE inhibitors","volume":"391","author":"Burki","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.022_bb0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.022_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Research Reviews"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/00207454.2015.1015722","article-title":"The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: A meta-analysis AU\u2013Cheng, Huawei","volume":"126","author":"Cheng","year":"2016","journal-title":"International Journal of Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Archives of Neurology"},{"issue":"6075","key":"10.1016\/bs.irn.2020.03.022_bb0075","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"issue":"21","key":"10.1016\/bs.irn.2020.03.022_bb0080","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2020.03.022_bb0085","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer's & Dementia (New York, N. Y.)"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13195-019-0528-6","article-title":"Souvenaid in the management of mild cognitive impairment: An expert consensus opinion","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1016\/bs.irn.2020.03.022_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12999","article-title":"Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease","volume":"1367","author":"Cunnane","year":"2016","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"11","key":"10.1016\/bs.irn.2020.03.022_bb0105","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: Prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"The Journal of Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: Enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nature Reviews. Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.022_bb0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau3333","article-title":"Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors","volume":"5","author":"Dominy","year":"2019","journal-title":"Science Advances"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2020.03.022_bb0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2010.02.036","article-title":"Etazolate improves performance in a foraging and homing task in aged rats","volume":"634","author":"Drott","year":"2010","journal-title":"European Journal of Pharmacology"},{"issue":"11","key":"10.1016\/bs.irn.2020.03.022_bb0130","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jalz.2019.06.4946","article-title":"Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial","volume":"15","author":"Ehrhardt","year":"2019","journal-title":"Alzheimer's & Dementia"},{"issue":"21","key":"10.1016\/bs.irn.2020.03.022_bb0135","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-alpha levels in patients with Alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2020.03.022_bb0140","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/npp.2010.32","article-title":"Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: Mechanisms involving a reduced amyloid and tau pathology","volume":"35","author":"Escribano","year":"2010","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"30","key":"10.1016\/bs.irn.2020.03.022_bb0145","doi-asserted-by":"crossref","first-page":"11141","DOI":"10.1073\/pnas.0403921101","article-title":"Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice","volume":"101","author":"Etcheberrigaray","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1016\/bs.irn.2020.03.022_bb0155","doi-asserted-by":"crossref","first-page":"7420796","DOI":"10.1155\/2017\/7420796","article-title":"Antidiabetic drugs in Alzheimer's disease: Mechanisms of action and future perspectives","volume":"2017","author":"Femminella","year":"2017","journal-title":"Journal of Diabetes Research"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: Study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"10.1016\/bs.irn.2020.03.022_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.07.010","article-title":"The challenges and promise of targeting the liver X receptors for treatment of inflammatory disease","volume":"181","author":"Fessler","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.022_bb0170","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3233\/JAD-132042","article-title":"Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: The OmegAD study","volume":"42","author":"Freund-Levi","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13543784.2017.1267726","article-title":"AVP-786 for the treatment of agitation in dementia of the Alzheimer's type","volume":"26","author":"Garay","year":"2017","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.irn.2020.03.022_bb0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"45","key":"10.1016\/bs.irn.2020.03.022_bb0195","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1523\/JNEUROSCI.3203-08.2008","article-title":"Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau","volume":"28","author":"Green","year":"2008","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.022_bb0200","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: Two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.022_bb0205","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: Two phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Current Alzheimer Research"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"Pt. A","key":"10.1016\/bs.irn.2020.03.022_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiology of Disease"},{"issue":"7S_Part_31","key":"10.1016\/bs.irn.2020.03.022_bb0220","doi-asserted-by":"crossref","first-page":"P1622","DOI":"10.1016\/j.jalz.2018.07.212","article-title":"P4\u2013388: Trailblazer-Alz (NCT03367403): A phase 2 disease-modification combination therapy trial targeting multiple mechanisms of action along the amyloid pathway","volume":"14","author":"Irizarry","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.022_bb0225","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of Abeta","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/bs.irn.2020.03.022_bb0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Frontiers in Neuroscience"},{"issue":"12","key":"10.1016\/bs.irn.2020.03.022_bb0235","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","article-title":"Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis","volume":"209","author":"Kim","year":"2012","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: A PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimer's Research & Therapy"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the insulin sensitizer metformin in Alzheimer disease: Pilot data from a randomized placebo-controlled crossover study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.022_bb0250","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1074\/jbc.M411420200","article-title":"The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease","volume":"280","author":"Koldamova","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0255","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5056\/jnm18087","article-title":"Brain-gut-microbiota axis in Alzheimer's disease","volume":"25","author":"Kowalski","year":"2019","journal-title":"Journal of Neurogastroenterology and Motility"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1447-0594.2011.00746.x","article-title":"Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease","volume":"12","author":"Kume","year":"2012","journal-title":"Geriatrics & Gerontology International"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.022_bb0265","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.023","article-title":"Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat","volume":"23","author":"Kurata","year":"2014","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"key":"10.1016\/bs.irn.2020.03.022_bb0270","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-8-18","article-title":"Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP\/PS1 mice","volume":"8","author":"LaClair","year":"2013","journal-title":"Molecular Neurodegeneration"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0275","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-Abeta40 vaccine (ABvac40) in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2010.06.045","article-title":"The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease","volume":"481","author":"Lee","year":"2010","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.irn.2020.03.022_bb0285","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuroscience.2017.07.053","article-title":"Amelioration of amyloid beta-induced retinal inflammatory responses by a LXR agonist TO901317 is associated with inhibition of the NF-kappaB signaling and NLRP3 inflammasome","volume":"360","author":"Lei","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.022_bb0290","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuropharm.2019.02.023","article-title":"Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe\/PS1dE9 mice","volume":"150","author":"Lesuis","year":"2019","journal-title":"Neuropharmacology"},{"issue":"39","key":"10.1016\/bs.irn.2020.03.022_bb0295","first-page":"2743","article-title":"Effects of telmisartan on the level of Abeta1-42, interleukin-1beta, tumor necrosis factor alpha and cognition in hypertensive patients with Alzheimer's disease","volume":"92","author":"Li","year":"2012","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"35","key":"10.1016\/bs.irn.2020.03.022_bb0300","doi-asserted-by":"crossref","first-page":"37061","DOI":"10.1074\/jbc.M403672200","article-title":"Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection","volume":"279","author":"Liao","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"21","key":"10.1016\/bs.irn.2020.03.022_bb0305","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","article-title":"Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis","volume":"34","author":"Liao","year":"2014","journal-title":"The Journal of Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2014A clinical study in Alzheimer's disease with a protofibril selective Abeta antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer's Research & Therapy"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0315","first-page":"242","article-title":"The Alzheimer's prevention initiative generation program: Evaluating CNP520 efficacy in the prevention of Alzheimer's disease","volume":"4","author":"Lopez Lopez","year":"2017","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"key":"10.1016\/bs.irn.2020.03.022_bb0320","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.trci.2019.02.005","article-title":"The Alzheimer's prevention initiative generation program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease","volume":"5","author":"Lopez Lopez","year":"2019","journal-title":"Alzheimer's & Dementia (New York, N. Y.)"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0325","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: Results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"Journal of Alzheimer's Disease"},{"issue":"8","key":"10.1016\/bs.irn.2020.03.022_bb0330","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1567205013666160404120817","article-title":"An anti-apoE4 specific monoclonal antibody counteracts the pathological effects of apoE4 in vivo","volume":"13","author":"Luz","year":"2016","journal-title":"Current Alzheimer Research"},{"issue":"7S_Part_31","key":"10.1016\/bs.irn.2020.03.022_bb0335","doi-asserted-by":"crossref","first-page":"P1623","DOI":"10.1016\/j.jalz.2018.07.213","article-title":"P4\u2013389: Elenbecestat, E2609, a bace inhibitor: Results from A phase-2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer's disease","volume":"14","author":"Lynch","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0340","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"Journal of Neurochemistry"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0345","doi-asserted-by":"crossref","first-page":"228","DOI":"10.14283\/jpad.2019.37","article-title":"Randomized, placebo controlled trial of NPT088, a phage-derived, amyloid-targeted treatment for Alzheimer's disease","volume":"6","author":"Michelson","year":"2019","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.022_bb0350","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbrc.2008.08.032","article-title":"Telmisartan prevented cognitive decline partly due to PPAR-gamma activation","volume":"375","author":"Mogi","year":"2008","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/bs.irn.2020.03.022_bb0355","unstructured":"Morgan D, H. D., Rochelle P, Paskus J (2019 ). \u201c2019 Alzheimer's drug pipeline\u2014The current state of Alzheimer's drug development.\u201d UsAgainstAlzheimer's (https:\/\/www.usagainstalzheimers.org\/sites\/default\/files\/RAAPages_FINAL.pdf)."},{"issue":"8","key":"10.1016\/bs.irn.2020.03.022_bb9005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer's disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Current Alzheimer Research"},{"issue":"11","key":"10.1016\/bs.irn.2020.03.022_bb0360","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/bs.irn.2020.03.022_bb0365","unstructured":"NIA National Institute on Aging (2020). \u201cTreatment of Alzheimer's disease\u2014How is Alzheimer's disease treated?\u201d https:\/\/www.nia.nih.gov\/health\/how-alzheimers-disease-treated."},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0370","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","article-title":"Fundamant: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1016\/bs.irn.2020.03.022_bb0375","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2015.04.020","article-title":"Lack of support for bexarotene as a treatment for Alzheimer's disease","volume":"100","author":"O'Hare","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0380","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer's Research & Therapy"},{"issue":"9","key":"10.1016\/bs.irn.2020.03.022_bb0385","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrneurol.2017.112","article-title":"The increasing burden of mortality from neurological diseases","volume":"13","author":"Pakpoor","year":"2017","journal-title":"Nature Reviews. Neurology"},{"issue":"11","key":"10.1016\/bs.irn.2020.03.022_bb0390","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/14737175.2018.1531706","article-title":"BACE inhibitors in clinical development for the treatment of Alzheimer's disease","volume":"18","author":"Panza","year":"2018","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.022_bb0395","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.neurobiolaging.2013.12.015","article-title":"Novel vaccine peptide GV1001 effectively blocks beta-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase","volume":"35","author":"Park","year":"2014","journal-title":"Neurobiology of Aging"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0400","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.etap.2014.01.008","article-title":"Anti-amyloidogenic effects of ID1201, the ethanolic extract of the fruits of Melia toosendan, through activation of the phosphatidylinositol 3-kinase\/Akt pathway","volume":"37","author":"Park","year":"2014","journal-title":"Environmental Toxicology and Pharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174470","article-title":"Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson's disease","volume":"12","author":"Paterniti","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/JAD-150405","article-title":"Targretin improves cognitive and biological markers in a patient with Alzheimer's disease","volume":"49","author":"Pierrot","year":"2016","journal-title":"Journal of Alzheimer's Disease"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0415","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: A randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimer's Research & Therapy"},{"issue":"17","key":"10.1016\/bs.irn.2020.03.022_bb0420","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.022_bb0425","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease","volume":"10","author":"Rafii","year":"2014","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.05.023","article-title":"Multiscale analysis of independent Alzheimer's cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus","volume":"99","author":"Readhead","year":"2018","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.022_bb0435","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0440","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.mcn.2007.01.011","article-title":"The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease","volume":"34","author":"Riddell","year":"2007","journal-title":"Molecular and Cellular Neurosciences"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0445","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"The Pharmacogenomics Journal"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0450","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer's disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Human Gene Therapy. Clinical Development"},{"key":"10.1016\/bs.irn.2020.03.022_bb0455","article-title":"Agitation, oxidative stress, and cytokines in Alzheimer disease: Biomarker analyses from a clinical trial with nabilone for agitation","author":"Ruthirakuhan","year":"2019","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1016\/bs.irn.2020.03.022_bb0460","doi-asserted-by":"crossref","first-page":"100385","DOI":"10.1016\/j.conctc.2019.100385","article-title":"Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial","volume":"15","author":"Ruthirakuhan","year":"2019","journal-title":"Contemporary Clinical Trials Communications"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0465","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimer's Research & Therapy"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0470","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12031-015-0665-8","article-title":"Liver X receptor agonist modifies the DNA methylation profile of synapse and neurogenesis-related genes in the triple transgenic mouse model of Alzheimer's disease","volume":"58","author":"Sandoval-Hernandez","year":"2016","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/bs.irn.2020.03.022_bb0475","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neulet.2016.04.007","article-title":"LXR activation protects hippocampal microvasculature in very old triple transgenic mouse model of Alzheimer's disease","volume":"621","author":"Sandoval-Hernandez","year":"2016","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0480","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13063-017-2406-5","article-title":"The apathy in dementia methylphenidate trial 2 (ADMET 2): Study protocol for a randomized controlled trial","volume":"19","author":"Scherer","year":"2018","journal-title":"Trials"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0485","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer's disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0490","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/psyg.12191","article-title":"Mirtazapine does not improve sleep disorders in Alzheimer's disease: Results from a double-blind, placebo-controlled pilot study","volume":"17","author":"Scoralick","year":"2017","journal-title":"Psychogeriatrics"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.022_bb0495","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Molecular Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.022_bb0500","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s13311-019-00767-8","article-title":"Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders","volume":"16","author":"Singh","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.irn.2020.03.022_bb0505","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuropharm.2012.11.009","article-title":"Etazolate, an alpha-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice","volume":"67","author":"Siopi","year":"2013","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0510","doi-asserted-by":"crossref","DOI":"10.1093\/cdn\/nzz003","article-title":"An experimental ketogenic diet for Alzheimer disease was nutritionally dense and rich in vegetables and avocado","volume":"3","author":"Taylor","year":"2019","journal-title":"Current Developments in Nutrition"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.022_bb0515","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1096\/fj.08-121392","article-title":"Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin","volume":"23","author":"Tippmann","year":"2009","journal-title":"The FASEB Journal"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0520","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: A randomized clinical trial","volume":"77","author":"Tsai","year":"2019","journal-title":"JAMA Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.022_bb0525","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer's disease: A 3-month, randomized, placebo-controlled, double-blind study","volume":"8","author":"Vellas","year":"2011","journal-title":"Current Alzheimer Research"},{"issue":"16","key":"10.1016\/bs.irn.2020.03.022_bb0530","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.022_bb0535","first-page":"474","article-title":"Effect of rosiglitazone on amyloid precursor protein processing and Abeta clearance in streptozotocin-induced rat model of Alzheimer's disease","volume":"20","author":"Wang","year":"2017","journal-title":"Iranian Journal of Basic Medical Sciences"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.022_bb0540","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Research"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.022_bb0545","first-page":"236","article-title":"Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies","volume":"4","author":"West","year":"2017","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0550","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: Cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"issue":"30","key":"10.1016\/bs.irn.2020.03.022_bb0555","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.1523\/JNEUROSCI.2262-17.2018","article-title":"Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: Implications for Alzheimer's disease risk reduction and early intervention","volume":"38","author":"Wu","year":"2018","journal-title":"The Journal of Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.022_bb0560","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ageing\/afx045","article-title":"Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: A phase II multicenter randomised controlled trial","volume":"46","author":"Xiao","year":"2017","journal-title":"Age and Ageing"},{"issue":"12","key":"10.1016\/bs.irn.2020.03.022_bb0565","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.tins.2014.08.004","article-title":"Lost after translation: Missorting of tau protein and consequences for Alzheimer disease","volume":"37","author":"Zempel","year":"2014","journal-title":"Trends in Neurosciences"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.022_bb0570","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41598-018-19641-2","article-title":"Cromolyn reduces levels of the Alzheimer's disease-associated amyloid beta-protein by promoting microglial phagocytosis","volume":"8","author":"Zhang","year":"2018","journal-title":"Scientific Reports"},{"issue":"16","key":"10.1016\/bs.irn.2020.03.022_bb0575","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1074\/jbc.M113.526095","article-title":"Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor\/retinoic acid receptor pathway","volume":"289","author":"Zhao","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.022_bb0580","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.bmcl.2010.01.005","article-title":"Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors","volume":"20","author":"Zhu","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"}],"container-title":["International Review of Neurobiology","Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:12:05Z","timestamp":1758748325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774220300532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128200766"],"references-count":117,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2020.03.022","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}